Gregory J Riely MD PhD

Oncology•New York, NY

Thoracic Cancer

Attending Physician Thoracic Oncology Service, Department of Medicine, Memorial Hospital Member Memorial Sloan Kettering Cancer Center

Request appointment

1275 York AveNew York, NY 10065
Book by Phone+1(765) 410-7109

Overview of Dr. Riely

Dr. Gregory Riely is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Case Western Reserve University School of Medicine and has been in practice 25 years. Dr. Riely accepts several types of health insurance, listed below. He is one of 529 doctors at Memorial Sloan Kettering Cancer Center and one of 87 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2003
Case Western Reserve University School of MedicineClass of 2001

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2003 - 2028
NJ State Medical License 2022 - 2027
NC State Medical License 2020 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2016-2017
CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017

Clinical Trials

Study of Salirasib to Treat Non-Small Cell Lung Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 2
Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib Start of enrollment: 2006 Jun 01
Completed
Phase 2
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors Start of enrollment: 2007 Dec 01
Completed
Phase 1

Publications & Presentations

PubMed

Brief Report: Intestinal Lymphangiectasia With Selpercatinib and Pralsetinib Treatment.
Jaime Rubio-Perez, Sameh Daher, Sabrina T Lin, Clare Wilhelm, Ling Feng Ye
Journal of Thoracic Oncology. 2026-08-01
Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non-Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART).
Andreas Rimner, Emily S Lebow, Kelly J Fitzgerald, Leah Kratochvil, Nicolas Toumbacaris
Journal of Clinical Oncology. 2026-07-16
Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non-Small Cell Lung Cancers from the PHAROS Study.
Gregory J Riely, Jean-François Martini, Norberto Pantoja Galicia, Brian Tunquist, Keith Wilner
Cancer Research Communications. 2026-07-01

Journal Articles

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung Cancers
Helena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology
PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET Exon 14 Altered Lung Cancers
G J Riely, J Dienstag, C Mrad, J K Sabari, M G Kris, K C Arbour, N Rekhtman, A J Plodkowski, P K Paik, B T Li, I Bergagnini, M D Offin, C M Rudin, L M Sholl, Annals of Oncology
YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical Genomics
Emmet J Jordan, Helena A Yu, Yelena Y Janjigian, Mark G Kris, Paul K Paik, Jamie E Chaft, Lu Wang, Gregory J Riely, Proceedings of the National Academy of Sciences

Lectures

Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC.
2019 ASCO Annual Meeting - 6/1/2019
American Society for Radiation Oncology(ASTRO): 20th Chicago Multidisciplinary Symposium inThoracic Oncology
American Society for Radiation Oncology, Chicago, Illinois - 9/6/2012
Treating Stage I to III Non-Small-Cell Lung Cancer With Limited Evidence
2013 International Conference, Philadelphia, Pennsylvania, USA

Press Mentions

Patients Benefit from a Comprehensive Program That Focuses on Cancer Treatment and Addresses Their Tobacco AddictionMay 30th, 2025
Lung Cancer Patients Who Never Smoked Often Carry Mutations like EGFRMay 26th, 2025
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerSeptember 14th, 2024

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
Great West PPO
Humana ChoiceCare Network PPO
Kaiser Permanente
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment